Key result
In murine models, loss of MYBPC3 altered the hyperplastic to hypertrophic transition phase of postnatal heart development, leading to increased cardiomyocyte endoreplication and rapid cardiomyopathy.
Why the study?
Does manipulation of MYBPC3 expression or CDK4/6 inhibition alter postnatal heart development and cardiomyopathy progression in murine models?
Does manipulation of MYBPC3 expression or CDK4/6 inhibition alter postnatal heart development and cardiomyopathy progression in murine models?
Alterations in sarcomere function modify the hyperplastic to hypertrophic transition phase of postnatal heart development, and targeting cell cycle pathways can counteract cardiomyopathic stimuli in MYBPC3-null mice.
MYBPC3 loss disrupts murine postnatal cardiomyocyte maturation; hypothesis-generating for cell-cycle targeting in human cardiomyopathy.
It remains unclear how perturbations in cardiomyocyte sarcomere function alter postnatal heart development. We utilized murine models that allowed manipulation of cardiac myosin-binding protein C (MYBPC3) expression at critical stages of cardiac ontogeny to study the response of the postnatal heart to disrupted sarcomere function. We discovered that the hyperplastic to hypertrophic transition phase of mammalian heart development was altered in mice lacking MYBPC3 and this was the critical period for subsequent development of cardiomyopathy. Specifically, MYBPC3-null hearts developed evidence of increased cardiomyocyte endoreplication, which was accompanied by enhanced expression of cell cycle stimulatory cyclins and increased phosphorylation of retinoblastoma protein. Interestingly, this response was self-limited at later developmental time points by an upregulation of the cyclin-dependent kinase inhibitor p21. These results provide valuable insights into how alterations in sarcomere protein function modify postnatal heart development and highlight the potential for targeting cell cycle regulatory pathways to counteract cardiomyopathic stimuli.
No takes yet. Share an insight, caveat, or question.
Nixon et al. (2017) studied Sarcomeric cardiomyopathy. MYBPC3 deletion/reactivation and CDK4/6 inhibition (PD-0332991) vs. Control mice or vehicle was evaluated on Cardiomyopathy development (heart mass, systolic function, cardiomyocyte endoreplication). In murine models, loss of MYBPC3 altered the hyperplastic to hypertrophic transition phase of postnatal heart development, leading to increased cardiomyocyte endoreplication and rapid cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: